AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21307816
Drug: meclizine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meclizine (50 mg)
Trial: 21307816
Drug: cinnarizine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cinnarizine (20 mg) + dimenhydrinate (40 mg)
Trial: 21307816
Drug: promethazine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: promethazine (25 mg) + dextro‐amphetamine (5 mg)
Trial: 18294083
Drug: OROS methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS methylphenidate (72 mg)
Trial: 16950962
Drug: Mixed amphetamine
RxNorm normalized name: mixed amphetamine salts 5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed amphetamine salts extended release (30 mg)
Trial: 15597521
Drug: Hydroxyurea (HU)
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (HU) 1000 mg qd
Trial: 15597521
Drug: Hydroxyurea (HU)
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (HU) 1500 mg qd
Trial: 15597521
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ddI plus HU
Trial: 11374699
Drug: High-dose ursodeoxycholic
RxNorm normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ursodeoxycholic acid (UDCA) 25-30 mg/kg per day
Trial: 9018022
Drug: Remoxipride (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride (150 mg)
Trial: 9018022
Drug: Sulpiride (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (300 mg)
Trial: 3525023
Drug: PY 108-068
RxNorm normalized name: KETOCONAZ 2% GEL/ZINC PY 1% SHAMPOO KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PY 108-068 (75 mg)
Trial: 24871787
Drug: DA-9601 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-9601 (60 mg, thrice daily)
Trial: 24871787
Drug: Misoprostol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (200 μg, thrice daily)
Trial: 20537558
Drug: Scopolamine patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine patch (1.5 mg)
Trial: 18237269
Drug: 90-microg dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90-microg dose of H5N1 influenza vaccine
Trial: 18237269
Drug: 45-microg dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45-microg dose of H5N1 influenza vaccine
Trial: 18237269
Drug: 15-microg dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-microg dose of H5N1 influenza vaccine
Trial: 18237269
Drug: 7.5-microg dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5-microg dose of H5N1 influenza vaccine
Trial: 18237269
Drug: H5N1 influenza
RxNorm normalized name: influenza, H5N1-1203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H5N1 influenza vaccine (third dose)
Trial: 12830564
Drug: Specialist outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialist outpatient treatment in specialist eating disorder clinics.
Trial: 31283835
Drug: Pre-operative CRP
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative CRP ≥5 mg/dL
Trial: 28132701
Drug: SBIRT intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SBIRT intervention (screening, brief intervention, and referral to treatment)
Trial: 24879388
Drug: Oral Glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Glucose Tolerance Test (OGTT) with 25g glucose
Trial: 24879388
Drug: Isoglycaemic intravenous
RxNorm normalized name: ioglycamic acid
DrugBank: Ioglycamic acid (DB13741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoglycaemic intravenous glucose infusion (IIGI)
Trial: 24879388
Drug: Oral Glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Glucose Tolerance Test (OGTT) with 75g and 125g glucose
Trial: 11772900
Drug: Diabetes medication
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes medication or weight-reduction program for patients with IGT
Trial: 9682550
Drug: Subgingival scaling
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgingival scaling using ultrasonic scalers and local anaesthesia plus systemic metronidazole (200 mg tds for 7 days)
Trial: 9682550
Drug: Subgingival scaling
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgingival scaling using ultrasonic scalers and local anaesthesia plus two applications of 25% metronidazole gel one week apart
Trial: 9234259
Drug: 125I‐B72.3 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125I‐B72.3 (1 mg)
Trial: 9234259
Drug: 125I‐B72.3 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125I‐B72.3 (20 mg)
Trial: 9234259
Drug: 131I‐CC49 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 131I‐CC49 (1 mg)
Trial: 9234259
Drug: 131I‐CC49 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 131I‐CC49 (20 mg)
Trial: 2920999
Drug: Propranolol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (15 mg intravenous single dose)
Trial: 2920999
Drug: Propranolol (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (160 mg per day chronic oral administration)
Trial: 2920999
Drug: Placebo (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (15 mg intravenous single dose)
Trial: 2920999
Drug: Placebo (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (160 mg per day chronic oral administration)
Trial: 28062685
Drug: Predictive scoring
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictive scoring model for all-cause 30 day mortality based on logistic regression including factors such as age >50 years, infection due to Klebsiella spp., source other than urinary tract, fatal underlying disease, Pitt score >3, severe sepsis or septic shock at presentation, and inappropriate early targeted therapy.
Trial: 23914988
Drug: Metyrapone 500
RxNorm normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metyrapone 500 mg twice daily
Trial: 21565593
Drug: Psychophysiological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychophysiological treatment (PT), 10 sessions, manualized, individually-administered
Trial: 21565593
Drug: Psychophysiological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychophysiological treatment (PT)
Trial: 19593170
Drug: Algorithm-guided standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm-guided standardized stepwise drug treatment regimen (SSTR)
Trial: 17227922
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors (optimized medical therapy)
Trial: 31823111
Drug: No-treatment condition
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment condition (control)
Trial: 26120980
Drug: Baclosan in
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baclosan in combination with standard therapy
Trial: 21940214
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus rituximab
Trial: 21940214
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus rituximab (favourable subgroup, IPI=0, no bulk)
Trial: 21940214
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (less favourable subgroup, IPI=1 or bulk, or both)
Trial: 19069803
Drug: Magneto-laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magneto-laser therapy
Trial: 1294818
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment administered during RA remission
Trial: 6199450
Drug: Cibenzoline (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline (maximum dose)
Trial: 29661916
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion (CSII) with real-time continuous glucose monitoring (RT-CGM)
Trial: 29661916
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injections (MDIs) with self-monitoring of blood glucose (SMBG)
Trial: 25886108
Drug: Granisetron 1
RxNorm normalized name: granisetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 1 mg with dexamethasone 8 mg
Trial: 25886108
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg with dexamethasone 8 mg
Trial: 25886108
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg alone (Control Group)
Trial: 18506738
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg ambroxol
Trial: 15937908
Drug: Fulvestrant (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant (250 mg monthly)
Trial: 12473476
Drug: Sterillium Gel
RxNorm normalized name: Trillium erectum extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterillium Gel (85% ethanol-based) applied under occlusive patch during induction phase (nine applications over three weeks) and one application during challenge phase.
Trial: 12473476
Drug: Sterillium Gel
RxNorm normalized name: Trillium erectum extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterillium Gel applied twice a day to the forearm for 14 days.
Trial: 9838800
Drug: Protein supplementation
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplementation (20 g/day, 5 days/week)
Trial: 7814240
Drug: Low-fat spread
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat spread (40% fat wt/wt) containing 8 g of fish oil per 100 g of product (Group B)
Trial: 7814240
Drug: High-fat spread
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat spread (80% fat wt/wt) containing 8 g of fish oil per 100 g of product (Group C)
Trial: 322782
Drug: Haloperidol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (3 mg daily)
Trial: 29737733
Drug: Voice training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice training (6 hours of intensive vocal therapy one week before surgery)
Trial: 17845590
Drug: Budesonide/formoterol 160/4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 160/4.5 microg b.i.d. plus additional doses as needed (SMART)
Trial: 9424683
Drug: Methadone (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (Group M) - 9 mg‐18 mg/24 h in epidural perfusion
Trial: 7946161
Drug: doxazosin, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxazosin, 4 mg daily
Trial: 3429068
Drug: Sulbenicillin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulbenicillin (2 g i.m. every 12 h for 7 days)
Trial: 3429068
Drug: Piperacillin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin (2 g i.m. every 12 h for 7 days)
Trial: 29274733
Drug: Cognitive Remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Remediation Treatment (CRT)
Trial: 29164824
Drug: Cognitive Remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Remediation Treatment (CRT) plus Motivational Interviewing (MI)
Trial: 29037157
Drug: TEA with
RxNorm normalized name: MENTHOL 4.1 mg ORAL LOZENGE [SUGAR FREE GREEN TEA WITH ECHINACEA COUGH SUPPRESSANT THROAT DROPS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEA with ropivacaine and morphine (Ep-RM)
Trial: 29037157
Drug: IV morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV morphine (IV-M)
Trial: 23165172
Drug: Physiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy plus botulinum toxin injection (BTX)
Trial: 21118844
Drug: Remifentanil 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0 µg kg⁻¹ min⁻¹
Trial: 21118844
Drug: Remifentanil 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.5 µg kg⁻¹ min⁻¹
Trial: 21118844
Drug: Remifentanil 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1.0 µg kg⁻¹ min⁻¹
Trial: 21118844
Drug: Remifentanil administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil administration
Trial: 16539549
Drug: Preemptive valdecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive valdecoxib 40 mg at least 30 minutes before initial archwire placement
Trial: 16539549
Drug: Postoperative valdecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative valdecoxib 40 mg two hours after initial archwire placement
Trial: 12907532
Drug: Warmed nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed nasal PD solutions (37 degrees C)
Trial: 12907532
Drug: Room temperature
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room temperature nasal PD solutions (22 degrees C)
Trial: 10638382
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of 4-androstene-3,17-dione (delta 4)
Trial: 10638382
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of 4-androstene-3 beta,17 beta‐diol (delta 4 Diol)
Trial: 8761562
Drug: Daily surveillance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily surveillance for illness and fortnightly malaria surveys in Group 1 schoolchildren.
Trial: 8761562
Drug: Two-monthly surveys
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-monthly surveys and weekly home visits in Group 2 subjects.
Trial: 3213310
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg fenoterol orally before PGE2-gel application
Trial: 3213310
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet before PGE2-gel application
Trial: 28116968
Drug: Subacromial infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subacromial infusion of local anesthetic (CSIA)
Trial: 19889524
Drug: Diet +
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet + PS (2 g/day)
Trial: 17337065
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose of 24 Gy or higher
Trial: 2568210
Drug: MK-912 2
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-912 2 mg
Trial: 2568210
Drug: MK-912 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-912 0.2 mg
Trial: 31374015
Drug: Xinnaoning capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinnaoning capsule (3 pills, 3 times daily for 12 weeks)
Trial: 28874142
Drug: cART with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cART with 800 mg efavirenz
Trial: 10875050
Drug: Paroxetine (20‐50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20‐50 mg/day)
Trial: 10875050
Drug: Paroxetine (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20, 40, or 60 mg/day)
Trial: 1399203
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg terbinafine twice daily
Trial: 1399203
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg terbinafine once daily
Trial: 30742915
Drug: Combination controller
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination controller therapy
Trial: 22154417
Drug: Magnetically guided
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetically guided capsule endoscope (MGCE)
Trial: 18617486
Drug: Oral co‐trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral co‐trimoxazole (per protocol analysis)
Trial: 27945464
Drug: Cevimeline 30
RxNorm normalized name: Cevimeline 30mg Oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cevimeline 30 mg TID (escalated to 45 mg TID if no improvement)
Trial: 11815395
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (500 mg daily for 2 months)
Trial: 10355512
Drug: Lansoprazole (LNS)
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole (LNS) 30 mg b.i.d. + clarithromycin (CLR) 250 mg b.i.d. + metronidazole (MTR) 250 mg q.i.d.
Trial: 10355512
Drug: Lansoprazole (LNS)
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole (LNS) 30 mg b.i.d. + amoxycillin (AMOX) 1 g b.i.d. + MTR 250 mg q.i.d.
Trial: 10355512
Drug: Lansoprazole (LNS)
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole (LNS) 30 mg b.i.d. + CLR 250 mg b.i.d. + AMOX 1 g b.i.d.
Trial: 8952741
Drug: Cibenzoline (260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline (260 mg/day, reduced to 130 mg/day for elderly patients)
Trial: 8952741
Drug: Propafenone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (600 mg/day, reduced to 300 mg/day for elderly patients)
Trial: 1682159
Drug: 120mg terfenadine
RxNorm normalized name: terfenadine 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120mg terfenadine twice daily for 4 weeks
Trial: 6756798
Drug: Corticosteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid treatment (halcinonide ointment, 0.1 percent)
Trial: 6756798
Drug: Placebo (ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (ointment base)
Trial: 28352069
Drug: N-Butylphthalide and
RxNorm normalized name: 3-n-butylphthalide
DrugBank: Butylphthalide (DB12749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-Butylphthalide and hyperbaric oxygen therapy (HBO)
Trial: 21819615
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (patients >58 years of age)
Trial: 21819615
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (APACHE II score >22)
Trial: 21819615
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (diabetic patients)
Trial: 21819615
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (patients on vasopressor therapy)
Trial: 21819615
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (admitted with severe sepsis)
Trial: 21819615
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (creatinine ≤ 100 μmol/L)
Trial: 21819615
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (GCS ≤ 9)
Trial: 21819615
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (simvastatin, equipotent doses ≥ 40 mg)
Trial: 20048489
Drug: Periarticular injection
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular injection with hyaluronic acid (HA) + standard of care (RICE)
Trial: 20048489
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection (PL) + standard of care (RICE)
Trial: 17334536
Drug: Lansoprazole (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (60 mg for 5 days)
Trial: 17334536
Drug: Lansoprazole treatment
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole treatment in H. pylori-positive group
Trial: 11280168
Drug: Ethanol (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.75 g/kg body wt)
Trial: 9426843
Drug: Acyclovir (ACV)
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyclovir (ACV) 3,200 mg/day for 3 months
Trial: 2949910
Drug: Human alpha-ANP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human alpha-ANP (1-28) infusion at 1.2 pmol min-1 kg-1 for 3 hours
Trial: 2949910
Drug: Human alpha-ANP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human alpha-ANP (1-28) infusion
Trial: 30629020
Drug: Enhanced recovery
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced recovery (nonopioid analgesia, patient-directed oral intake, early ambulation)
Trial: 30629020
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (opioid analgesia, physician-directed diet)
Trial: 30503129
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone co-treatment during IVF
Trial: 20002592
Drug: Optimized antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized antidepressant therapy for both depression and pain
Trial: 2145237
Drug: Enoximone, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone, 100 mg t.d.s. added to optimal therapy